140 related articles for article (PubMed ID: 35001083)
1. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study.
Parry MG; Nossiter J; Morris M; Sujenthiran A; Skolarus TA; Berry B; Nathan A; Cathcart P; Aggarwal A; van der Meulen J; Trinh QD; Payne H; Clarke NW
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):287-292. PubMed ID: 35001083
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.
Parry MG; Cowling TE; Sujenthiran A; Nossiter J; Berry B; Cathcart P; Aggarwal A; Payne H; van der Meulen J; Clarke NW; Gnanapragasam VJ
BMC Med; 2020 May; 18(1):114. PubMed ID: 32460859
[TBL] [Abstract][Full Text] [Related]
3. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.
Gnanapragasam VJ; Bratt O; Muir K; Lee LS; Huang HH; Stattin P; Lophatananon A
BMC Med; 2018 Feb; 16(1):31. PubMed ID: 29490658
[TBL] [Abstract][Full Text] [Related]
4. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer.
Gnanapragasam VJ; Barrett T; Thankapannair V; Thurtle D; Rubio-Briones J; Domínguez-Escrig J; Bratt O; Statin P; Muir K; Lophatananon A
BJU Int; 2019 Nov; 124(5):758-767. PubMed ID: 31063245
[TBL] [Abstract][Full Text] [Related]
5. Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.
Al Hussein Al Awamlh B; Wu X; Barocas DA; Moses KA; Hoffman RM; Basourakos SP; Lewicki P; Smelser WW; Arenas-Gallo C; Shoag JE
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):395-402. PubMed ID: 35882950
[TBL] [Abstract][Full Text] [Related]
6. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
7. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
8. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States.
Prasad SM; Gu X; Lipsitz SR; Nguyen PL; Hu JC
Cancer; 2012 Mar; 118(5):1260-7. PubMed ID: 21823112
[TBL] [Abstract][Full Text] [Related]
9. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
10. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
Dess RT; Hartman HE; Mahal BA; Soni PD; Jackson WC; Cooperberg MR; Amling CL; Aronson WJ; Kane CJ; Terris MK; Zumsteg ZS; Butler S; Osborne JR; Morgan TM; Mehra R; Salami SS; Kishan AU; Wang C; Schaeffer EM; Roach M; Pisansky TM; Shipley WU; Freedland SJ; Sandler HM; Halabi S; Feng FY; Dignam JJ; Nguyen PL; Schipper MJ; Spratt DE
JAMA Oncol; 2019 Jul; 5(7):975-983. PubMed ID: 31120534
[TBL] [Abstract][Full Text] [Related]
11. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
12. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
13. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
14. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
15. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
17. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
18. Organisation of Prostate Cancer Services in the English National Health Service.
Aggarwal A; Nossiter J; Cathcart P; van der Meulen J; Rashbass J; Clarke N; Payne H
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):482-489. PubMed ID: 26947316
[TBL] [Abstract][Full Text] [Related]
19. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.
Tang C; Hoffman KE; Allen PK; Gabel M; Schreiber D; Choi S; Chapin BF; Nguyen QN; Davis JW; Corn P; Logothetis C; Ward J; Frank SJ; Navai N; McGuire SE; Anscher M; Pisters L; Pettaway CA; Kumar R; Linson P; Tripuraneni P; Tomaszewski JJ; Patel AB; Augspurger M; Kuban DA
Cancer; 2020 Feb; 126(3):506-514. PubMed ID: 31742674
[TBL] [Abstract][Full Text] [Related]
20. Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England.
Parry MG; Boyle JM; Nossiter J; Morris M; Sujenthiran A; Berry B; Cathcart P; Aggarwal A; van der Meulen J; Payne H; Clarke NW
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):257-263. PubMed ID: 34493837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
